Health e-Baby: Trial to Reduce Obesity Risk Factors During the First 1,000 Days
NCT ID: NCT05225649
Last Updated: 2024-11-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2022-01-14
2024-09-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The main outcomes are feasibility of the intervention components and data collection. Study will use maternal body mass index (BMI) and child weight-for-length outcomes to estimate sample size needed for a full-scale trial to test intervention efficacy. Primary analysis for full-scale trial power and sample size calculations will be conducted using child weight-for-length data at Child Age 12 Months Visit. Data collected will inform future interventions.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Starting Early Obesity Prevention Program
NCT01541761
BabyQ's: Randomized Controlled Trial of Health Messaging in Pregnancy and Infancy
NCT04238585
Reducing Obesity and Type 2 Diabetes in High Risk Youth
NCT01560676
Assessment of Risk Factors for Childhood Obesity and Nutrition Education Intervention on Infant Growth and Development
NCT04047888
Starting Early to Prevent Obesity Using Telehealth (StEP OUT): Pilot RCT
NCT07254065
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The overall goal of this study is to test the feasibility of a pilot randomized controlled trial to promote healthy maternal weight in pregnancy and post-partum and normal child weight-for-length from birth to age 12 months. The study will include 50 women (enrollment up to 70 to account for potential attrition) in pregnancy and their child through age 12 months to examine rates of study component completion, study component satisfaction, and retention. Women enrolled in the intervention will participate in virtual health coaching and receive self-directed behavior change materials by text and email. The results of this study will help us develop efficacious childhood obesity prevention interventions and determine how many study participants would be needed for a full-scale trial. Ultimately, this research could open new avenues for studying ways to promote health starting early in life.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Behavior Change Intervention
Participants will receive health coaching, patient-directed behavior change support by mobile health, and usual clinical care.
Behavior Change Intervention
Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
Control
Participants will receive usual clinical care.
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Behavior Change Intervention
Health coaching sessions; self-monitoring: Fitbit, home scale, and app; personalized health information by mobile health: growth charts and age-specific health behavior information via text message and email; behavior change support by mobile health: family-based health behavior goal setting via chatbot; and usual clinical care.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Gestational age 10-20 weeks at time of enrollment
* Receiving primary care or prenatal care at Columbia/New-York Presbyterian site
* Planned delivery at Columbia/New-York Presbyterian with planned continuation of primary care (postpartum and pediatric) at Columbia/New-York Presbyterian
* Ability to read and respond to questions in English or Spanish
* Smart phone ownership
* Willingness to receive information by smart phone for 18-month intervention and follow-up duration
* Willingness to be randomized into an observational study or an intervention and complete all study components
* Gives permission to participate in receiving messages to their smart phone and email
* Gives permission to complete all study procedures
* Has a physician's clearance for light to moderate physical activity
* Has an active email address
* Capable of providing informed consent
* Has access to Wi-Fi connection in their household
Exclusion Criteria
* Pre-pregnancy body mass index \<18.5 kg/m2 \>40
* Major fetal anomaly
* Fetal genetic abnormality
* Planned termination of pregnancy
* Chronic medical conditions that affect nutrition or prohibit regular exercise or alter weight status such as:
* Diseases associated with glucose metabolism
* Diabetes (Type 1, type 2)
* Inflammatory Bowel Disease (Crohn's disease, ulcerative colitis)
* History of gastric bypass/gastric sleeve
* Uncontrolled thyroid disease (hypo or hyperthyroidism)
* Condition requiring enteral tube feeding
* Congenital or acquired heart disease that impacts nutritional needs and physical activity ability
* HIV/AIDS
* Kidney disease
* Cancer
* Uncontrolled autoimmune disease
* Lupus
* Multiple sclerosis
* Sickle cell disease
* Zika infection
* Taking or planning to take certain prescription medications including high dose glucocorticoids, atypical antipsychotics associated with weight gain (such as risperdal (risperidone), clozapine (clozaril), olanzapine (zyprexa), quetiapine (seroquel), etc.), or other prescription weight loss medications
* Personal history of breast cancer or any other type of cancer other than a basal cell skin cancer
* Personal history of cardiovascular disease (coronary artery disease, congestive heart failure, valvular heart disease, stroke, transient ischemic attack, or intermittent claudication), kidney disease, liver disease, venous or arterial thromboembolic disease, adrenal insufficiency, depression requiring hospitalization within the past 6 months, or non-pregnancy related illness requiring overnight hospitalization in the past 6 months
* Underlying disease/treatment that might interfere with participation in/completion of the study (e.g., significant gastrointestinal conditions, major psychiatric disorders, and others at the discretion of the study clinician)
* Other active medical problems detected by examination or laboratory testing
* Inability to complete study visits or intervention components
* Unwillingness or inability to commit to a 18-month research study for them or their child, including plans to move away
* Plans to be in a different geographic area within the next 2 years
* Unable to give informed consent
18 Years
50 Years
FEMALE
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Doris Duke Charitable Foundation
OTHER
Columbia University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ali Mencin, MD
Role: PRINCIPAL_INVESTIGATOR
Columbia University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Columbia University
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
AAAT7915
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.